XtalPi Inc. announced that it has received CNY 2.5918 billion in funding from OrbiMed Advisors LLC, RRJ Capital, Sequoia China Investment Management LLP, Sino Biopharmaceutical Limited, 5Y Capital, HOPU Jinghua Investment Consultancy Co., Ltd.
XtalPi Inc. announced it has received $400 million (CNY 2.5918 billion) in its series D round of funding led by OrbiMed Advisors LLC and RRJ Capital on August 11, 2021. The transaction also included participation from Sino Biopharmaceutical Limited, Hopu Fund, a fund managed by HOPU Jinghua (Beijing) Investment Consultancy Co., Ltd., returning investors Sequoia China Investment Management LLP and 5Y Capital. The round was raised at a valuation of CNY 13 billion.